EGFR-mutated non-small-cell lung cancer transformation into small-cell lung cancer after tyrosine kinase inhibitors: let us think about liquid biopsy!

被引：0
|
作者：
Pezzuto, F. [1 ]
Fortarezza, F. [1 ]
Lunardi, F. [1 ]
Tauro, V. [1 ]
Frega, S. [1 ]
Pasello, G. [1 ]
Calabrese, F. [1 ]
机构：
[1] Univ Padua, Padua, Italy
来源：
VIRCHOWS ARCHIV | 2021年 / 479卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
OFP-23-003
引用
收藏
页码：S50 / S50
页数：1
相关论文
共 50 条
  • [41] De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer
    Bozorgmehr, Farastuk
    Kazdal, Daniel
    Chung, Inn
    Kirchner, Martina
    Magios, Nikolaus
    Kriegsmann, Mark
    Allgaeuer, Michael
    Klotz, Laura, V
    Muley, Thomas
    El Shafie, Rami A.
    Fischer, Juergen R.
    Faehling, Martin
    Stenzinger, Albrecht
    Thomas, Michael
    Christopoulos, Petros
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [42] Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer
    Moriya, Tetsuji
    Hamaji, Masatsugu
    Yoshizawa, Akihiko
    Miyata, Ryo
    Noguchi, Misa
    Tamari, Shigeyuki
    Chiba, Naohisa
    Miyamoto, Hideaki
    Toyazaki, Toshiya
    Tanaka, Satona
    Yamada, Yoshito
    Yutaka, Yojiro
    Nakajima, Daisuke
    Ohsumi, Akihiro
    Menju, Toshi
    Date, Hiroshi
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2022, 34 (03) : 416 - 423
  • [43] Treatment strategy of EGFR-mutated non-small cell lung cancer
    Tanaka, Fumihiro
    Yoneda, Kazue
    Takenaka, Masaru
    Kuroda, Koji
    JOURNAL OF THORACIC DISEASE, 2022, 14 (03) : 602 - 606
  • [44] How to Treat EGFR-Mutated Non-Small Cell Lung Cancer
    Belani, Neel
    Liang, Katherine
    Fradley, Michael
    Judd, Julia
    Borghaei, Hossein
    JACC: CARDIOONCOLOGY, 2023, 5 (04): : 542 - 545
  • [45] Emerging drugs for EGFR-mutated non-small cell lung cancer
    Sukrithan, Vineeth
    Deng, Lei
    Barbar, Alexander
    Cheng, Haiying
    EXPERT OPINION ON EMERGING DRUGS, 2019, 24 (01) : 5 - 16
  • [46] Safety of osimertinib in EGFR-mutated non-small cell lung cancer
    Mezquita, Laura
    Varga, Andreea
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1239 - 1248
  • [47] Systemic treatment of EGFR-mutated non-small cell lung cancer
    Czyzykowski, Rafal L.
    Wrona, Ewa K.
    Talajko, Agata
    Hasinska, Aleksandra M.
    Potemski, Piotr J.
    ONCOLOGY IN CLINICAL PRACTICE, 2024,
  • [48] Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer
    Aredo, Jacqueline V.
    Wakelee, Heather A.
    Hui, Angela Bik-Yu
    Padda, Sukhmani K.
    Joshi, Nitin D.
    Guo, H. Henry
    Chaudhuri, Aadel
    Diehn, Maximilian
    Loo, Billy W.
    Neal, Joel W.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 33
  • [49] EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer
    Kamel-Reid, S.
    Chong, G.
    Ionescu, D. N.
    Magliocco, A. M.
    Spatz, A.
    Tsao, M.
    Weng, X.
    Young, S.
    Zhang, T.
    Soulieres, D.
    CURRENT ONCOLOGY, 2012, 19 (02) : E67 - E74
  • [50] Continuation of Third-Generation Tyrosine Kinase Inhibitors in Second-Line Trials for EGFR-Mutated Non-Small-Cell Lung Cancer: Regulatory Considerations
    Goulart, Bernardo H. L.
    Larkins, Erin
    Beaver, Julia A.
    Singh, Harpreet
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (23) : 3905 - +
12345